Alnylam Pharmaceuticals Inc.
ALNY | NASDAQ
$244.32
+$4.76 (+1.99%)
At close: Sep 21, 2026, 4:00 PM ET
$244.35
+$0.03 (+0.01%)
After-hours:
Sep 21, 2026, 7:30 PM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.8B | 4.29B | 3.71B | 3.21B | 2.46B | 2.35B | 2.25B | 2.09B | 2.34B | 2B | 1.83B | 1.72B | 1.24B | 1.14B | 1.04B | 960.92M | 884.25M | 879.98M | 844.29M | 749.31M | 687.53M | 570.94M |
Cost of Revenue | 974.34M | 819.03M | 678.95M | 514.04M | 402.72M | 328.44M | 323.37M | 306.41M | 304.82M | 321.51M | 310.41M | 275.81M | 232.62M | 188.06M | 168.82M | 155.22M | 146.76M | 144.71M | 140.14M | 125.5M | 114.64M | 95.81M |
Gross Profit | 3.83B | 3.47B | 3.03B | 2.7B | 2.06B | 2.02B | 1.92B | 1.79B | 2.04B | 1.68B | 1.52B | 1.45B | 1B | 955.39M | 868.6M | 805.7M | 737.48M | 735.27M | 704.14M | 623.81M | 572.9M | 475.13M |
Operating Income | 999.78M | 752.14M | 501.58M | 264.7M | -180.19M | -115.37M | -176.89M | -188.13M | 102.64M | -175.8M | -282.18M | -354.39M | -826.29M | -788.15M | -785.07M | -791.02M | -714.66M | -669.13M | -708.65M | -708.31M | -751.84M | -804.53M |
Interest Income | 110.05M | 109.4M | 111.47M | 115.86M | 119.32M | 121.02M | 121.99M | 121.38M | 114.66M | 106.55M | 95.56M | 79.23M | 61.63M | 42.45M | 24.81M | 11.23M | 3.63M | 2.14M | 1.58M | 2.18M | 4.02M | 6.78M |
Pretax Income | 799.57M | 586.4M | 323.15M | -31.94M | -379.58M | -355.38M | -377.38M | -321.1M | -61.7M | -324.74M | -433.52M | -502.85M | -1.06B | -1.06B | -1.13B | -1.18B | -978.57M | -892.23M | -852.14M | -835.44M | -883.66M | -873.23M |
Net Income | 807.99M | 577.22M | 313.75M | 43.57M | -319.09M | -269.7M | -278.16M | -332.26M | -72.94M | -332.08M | -440.24M | -509.87M | -1.06B | -1.06B | -1.13B | -1.18B | -980.72M | -892.87M | -852.82M | -837.9M | -886.68M | -876.35M |
Selling & General & Admin | 1.32B | 1.29B | 1.21B | 1.18B | 1.08B | 1B | 975.53M | 878.31M | 856.49M | 822.78M | 795.65M | 807.87M | 844.55M | 799.85M | 770.66M | 746.7M | 652.91M | 628.25M | 620.64M | 600.55M | 625.95M | 608.52M |
Research & Development | 1.51B | 1.42B | 1.32B | 1.25B | 1.16B | 1.13B | 1.13B | 1.1B | 1.08B | 1.03B | 1B | 994.31M | 986.51M | 943.69M | 883.02M | 850.03M | 799.23M | 776.15M | 792.16M | 731.58M | 698.79M | 671.15M |
Other Expenses | 3.11M | 2.92M | 2.92M | 2.92M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -140K | -140K | -140K | -734K | -594K |
Operating Expenses | 2.83B | 2.72B | 2.53B | 2.43B | 2.24B | 2.14B | 2.1B | 1.98B | 1.94B | 1.86B | 1.8B | 1.8B | 1.83B | 1.74B | 1.65B | 1.6B | 1.45B | 1.4B | 1.41B | 1.33B | 1.32B | 1.28B |
Interest Expense | 325.07M | 283.27M | 252.63M | 162.26M | 152.24M | 145.25M | 141.86M | 134.23M | 130.74M | 127.52M | 121.22M | 119.8M | 129.99M | 142.56M | 155.97M | 162.87M | 162.06M | 152.87M | 143.02M | 134.72M | 123.18M | 117.01M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.8B | 3.53B | 3.21B | 2.95B | 2.64B | 2.46B | 2.43B | 2.28B | 2.24B | 2.18B | 2.11B | 2.08B | 2.06B | 1.93B | 1.82B | 1.75B | 1.6B | 1.55B | 1.55B | 1.46B | 1.44B | 1.38B |
Income Tax Expense | -39.75M | -22.14M | 9.41M | -75.51M | -60.49M | -85.68M | -99.22M | 11.16M | 11.24M | 7.33M | 6.73M | 7.01M | 4M | 4.92M | 4.16M | 1.85M | 2.15M | 649K | 680K | 2.46M | 3.02M | 3.12M |
Shares Outstanding (Basic) | 133.24M | 132.89M | 132.23M | 131.45M | 129.68M | 129.68M | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 125.22M | 124.66M | 124.11M | 123.27M | 122.17M | 120.9M | 120.17M | 119.77M | 118.9M | 117.77M | 117.08M |
Shares Outstanding (Diluted) | 138.25M | 138.23M | 136.28M | 137.35M | 129.68M | 129.68M | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 131.34M | 124.66M | 124.11M | 123.27M | 122.17M | 120.9M | 120.39M | 119.77M | 119.14M | 117.77M | 117.08M |
EPS (Basic) | 6.10 | 4.36 | 2.37 | 0.31 | -2.47 | -2.09 | -2.17 | -2.62 | -0.57 | -2.65 | -3.53 | -4.11 | -8.61 | -8.69 | -9.29 | -9.77 | -8.17 | -7.49 | -7.20 | -7.13 | -7.59 | -7.54 |
EPS (Diluted) | 5.92 | 4.21 | 2.26 | 0.24 | -2.47 | -2.09 | -2.17 | -2.62 | -0.60 | -2.68 | -3.56 | -4.14 | -8.61 | -8.69 | -9.29 | -9.77 | -8.17 | -7.49 | -7.20 | -7.13 | -7.59 | -7.54 |
EBITDA | 1.15B | 924.47M | 631.44M | 186.55M | -170.93M | -152.67M | -178.94M | -130.9M | 124.37M | -143.72M | -258.24M | -328.17M | -877.39M | -868.37M | -926.56M | -975.87M | -773.79M | -694.93M | -661.56M | -654.14M | -717.11M | -716.46M |
EBIT | 1.1B | 869.67M | 575.78M | 130.32M | -227.34M | -210.13M | -235.52M | -186.88M | 69.04M | -197.22M | -312.3M | -383.06M | -929.55M | -917.44M | -971.03M | -1.02B | -816.51M | -739.36M | -709.12M | -700.72M | -760.48M | -756.22M |
Depreciation & Amortization | 54.42M | 54.81M | 55.66M | 56.32M | 56.5M | 57.56M | 56.67M | 55.98M | 55.33M | 53.51M | 54.05M | 54.88M | 52.16M | 49.07M | 44.47M | 41.53M | 42.72M | 44.43M | 47.57M | 46.58M | 43.37M | 39.76M |
Add to Watchlist
Select watchlists to add or remove ALNY